Newest
-
Dongying’s Yellow River Estuary Winter Jujubes Head for European and North American Markets
-
MEXC Reports First $100 Million Launchpad Round as SpaceX Demand Spills Into Tokenized Stock Trading
-
PT. Otto Media Grup Holds Otto Beauty Matchmaking 2026, Promoting Efficient Connections Between Beauty Brands And Content Creators
-
Trump says he’s Iran’s ‘number one target’ for assassination after renewed strikes
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
2024-11-01
I-Mab Biopharma
HaiPress

ROCKVILLE,Md.,Oct. 31,2024 -- I-Mab (NASDAQ: IMAB) (the "Company"),a US-based,global biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that it plans to release financial results for the third quarter ended September 30,2024,on Thursday,November 14,pre-market Eastern Time.
The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline,corporate strategy,and objectives. Information about financial results,conference calls,webcasts,and other information is posted on the Company's website.
AboutI-Mab
I-Mab (NASDAQ: IMAB) is a US-based,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.
I-Mab has established operations in Rockville,Maryland,and Short Hills,New Jersey.For more information,please visithttps://www.i-mabbiopharma.comand followus onLinkedInandX.
I-Mab Investor & Media Contacts
Tyler Ehler
Senior Director,Investor Relations
IR@imabbio.com
